Document Detail

Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction.
MedLine Citation:
PMID:  19436656     Owner:  NLM     Status:  MEDLINE    
TNKase is a genetically engineered variant of the alteplase molecule. Three different mutations result in an increase of the plasma half-life, of the resistance to plasminogen-activator inhibitor 1 and of the thrombolytic potency against platelet-rich thrombi. Among available agents in clinical practice, TNKase is the most fibrin-specific molecule and can be delivered as a single bolus intravenous injection. Several large-scale clinical trials have enrolled more than 27,000 patients with acute myocardial infarction, making the use of this drug truly evidence-based. TNKase is equivalent to front-loaded alteplase in terms of mortality and is the only bolus thrombolytic drug for which this equivalence has been formally demonstrated. TNKase appears more potent than alteplase when symptoms duration lasts more than 4 hours. Also, TNKase significantly reduces the rate of major bleeds and the need for blood transfusions. The efficacy of TNKase may be further improved by enoxaparin substitution for unfractionated heparin, provided that enoxaparin dose adjustment is made for patients more than 75 years old. Hitherto, the small available randomized studies and international clinical registries suggest that pre-hospital TNKase is as effective as primary angioplasty, thus laying the foundations for a new fibrinolytic, TNKase-based strategy as the backbone of reperfusion in acute myocardial infarction.
Giovanni Melandri; Fabio Vagnarelli; Daniela Calabrese; Franco Semprini; Samuele Nanni; Angelo Branzi
Related Documents :
9257136 - Responding to symptoms and signs of acute myocardial infarction--how do you educate the...
8938286 - The effects of cardiopulmonary bypass on fibrin formation and lysis: is a normal fibrin...
3825886 - Prediction of infarct coronary artery recanalization after intravenous thrombolytic the...
8942226 - Causes of death from myocardial infarction before and after thrombolysis era: a patholo...
2878806 - The role of beta blockade in the limitation of infarct development.
17947936 - Risk of retinal microembolism after off-pump and on-pump coronary artery bypass surgery.
Publication Detail:
Type:  Journal Article; Review     Date:  2009-04-08
Journal Detail:
Title:  Vascular health and risk management     Volume:  5     ISSN:  1178-2048     ISO Abbreviation:  Vasc Health Risk Manag     Publication Date:  2009  
Date Detail:
Created Date:  2009-05-13     Completed Date:  2009-06-19     Revised Date:  2013-05-23    
Medline Journal Info:
Nlm Unique ID:  101273479     Medline TA:  Vasc Health Risk Manag     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  249-56     Citation Subset:  IM    
Dipartimento Cardiovascolare, Università di Bologna, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Balloon, Coronary
Blood Transfusion
Drug Administration Schedule
Drug Therapy, Combination
Emergency Medical Services
Fibrinolytic Agents / administration & dosage,  adverse effects,  therapeutic use*
Hemorrhage / chemically induced,  prevention & control
Injections, Intravenous
Myocardial Infarction / drug therapy*
Thrombolytic Therapy*
Tissue Plasminogen Activator / administration & dosage,  adverse effects,  therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Fibrinolytic Agents; 0/tenecteplase; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil.
Next Document:  Efficacy and safety of rosuvastatin in the management of dyslipidemia.